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Abstract
Introduction Long-term outcome data provide important insights into the clinical utility of enzyme replacement therapies. Such
data are presented for velmanase alfa in the treatment of alpha-mannosidosis (AM).
Methods Patient data (n = 33; 14 adults, 19 paediatric) from the clinical development programme for velmanase alfa were
integrated in this prospectively-designed analysis of long-term efficacy and safety. Patients who participated in the phase I/II
or phase III trials and were continuing to receive treatment after completion of the trials were invited to participate in a
comprehensive evaluation visit to assess long-term outcomes. Primary endpoints were changes in serum oligosaccharide and
the 3-minute stair climb test (3MSCT).
Results Mean (SD) treatment exposure was 29.3 (15.2) months. Serum oligosaccharide levels were significantly reduced in the
overall population at 12 months (mean change: –72.7%, P < 0.001) and remained statistically significant at last observation
(−62.8%, P < 0.001). A mean improvement of +9.3% in 3MSCTwas observed at 12 months (P = 0.013), which also remained
statistically significant at last observation (+13.8%, P = 0.004), with a more pronounced improvement detected in the paediatric
subgroup. No treatment-emergent adverse events were reported leading to permanent treatment discontinuation.
Conclusions Patients treated with velmanase alfa experienced improvements in biochemical and functional measures that were
maintained for up to 4 years. Long term follow-up is important and further supports the use of velmanase alfa as an effective and
well-tolerated treatment for AM. Based on the currently available data set, no baseline characteristic can be predictive of
treatment outcome. Early treatment during paediatric age showed better outcome in functional endpoints.
Keywords Alpha-mannosidosis . Recombinant human alpha-mannosidase . Lysosomal storage disorder . Enzyme replacement
therapy . Velmanase alfa . Integrated analysis
Introduction
Alpha-mannosidosis (AM) is a rare autosomal recessive lyso-
somal storage disorder with an estimated prevalence of one in
500,000–1,000,000 live births (Meikle et al 2004; Meikle et al
1999). Pathogenic sequence variants in the MAN2B1 gene
cause a reduction in the activity of lysosomal alpha-
mannosidase, resulting in impaired glycoprotein degradation
in the lysosomes, and ultimately, impaired cellular function
and apoptosis (Borgwardt et al 2015; Thomas 2001). AM
presents as a multi-systemic disease, characterised by immu-
nodeficiency, hearing impairment, facial and skeletal
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abnormalities and mental retardation, among other manifesta-
tions (Malm and Nilssen, 2008).
Other than supportive care, the only treatment option cur-
rently available for AM is allogeneic haematopoietic stem cell
transplantation (HSCT) from a human leukocyte antigens
(HLA)-matched donor, which has a variable outcome and
carries a serious morbidity and mortality risk (Mynarek et al
2012; Borgwardt et al 2014a).
Velmanase alfa is a recombinant human lysosomal alpha-
mannosidase, developed as intravenous (IV) enzyme replace-
ment therapy (ERT) for AM (Borgwardt et al 2013). In phase
I/II trials, velmanase alfa was associated with a sustained de-
crease in serum oligosaccharides after 18 months of therapy
(mean percentage change −89.9%, P < 0.001) and achievement
of an average improvement of 39 steps in the 3-minute stair
climb test (3MSCT; P = 0.004) (Borgwardt et al 2014b).
Velmanase alfa treatment was subsequently evaluated in a
phase III placebo-controlled randomised trial (NCT01681953;
Borgwardt et al 2017 [submitted]). Here we present long-term
outcomes in patients with AM treated with velmanase alfa.
Methods
Study design
This study is an integrated analysis of efficacy and safety
outcomes in patients with AM who participated in velmanase
alfa trials and received therapy for up to 4 years in follow-up
clinical trial or compassionate use (CU) programme.
Analysis population and database generation
Individual patient data from phase I/II (Borgwardt et al 2013)
and II I t r ia ls and the subsequent rhLAMAN-07
(NCT01908712), rhLAMAN-09 (NCT01908725) and
rhLAMAN-10 (NCT02478840) studies were integrated into
a single database. rhLAMAN-07 and rhLAMAN-09 are on-
going clinical trials of once-weekly 1 mg/kg velmanase alfa
treatment in patients from France, or from Poland and
Norway, respectively, who previously participated in
velmanase alfa trials. rhLAMAN-10 is a single-centre clinical
trial of 1 mg/kg velmanase alfa in which patients who had
previously participated in velmanase alfa clinical trials and
subsequently enrolled in the international CU programme
were invited to undergo a comprehensive evaluation visit (last
observation; LO). Inclusion/exclusion criteria are provided in
the Supplementary methods.
Patients had a confirmed diagnosis of AM, as defined by
alpha-mannosidase activity <10% of normal activity, who had
participated in the phase I/II and III trials, and were currently
receiving weekly IV infusions of velmanase alfa according to
their respective follow-up studies or CU programmes.
Procedures and treatment
All patients underwent clinical, functional and laboratory as-
sessments at baseline and at pre-specified time points accord-
ing to the protocol of their parental trial. Patients enrolled in
rhLAMAN-07, −09 and − 10 underwent a LO visit at the same
central location. In the rhLAMAN-10 trial, patients were
screened for eligibility on day 1 of the visit. Patients who
provided informed consent underwent pre-infusion evalua-
tions, and were given a single IV infusion of velmanase alfa
1 mg/kg on day 2.
Endpoints
Primary endpoints for this analysis were the change from base-
line to LO in serum oligosaccharides, and change from baseline
to LO in the 3MSCT. Serum oligosaccharides were measured
by high pressure liquid chromatography (HPLC) with ultravio-
let (UV) detection coupled with matrix-assisted laser
desorption/ionisation-time of flight (MALDI-TOF) mass spec-
trometry. Functional capacity was further assessed using the 6-
minute walk test (6MWT), forced vital capacity (FVC % pre-
dicted and l, measured by spirometry), and Bruininks-
Oseretsky test of motor proficiency (BOT-2). Immunological
status was assessed as serum immunoglobulin G (IgG) concen-
trations and presence of hypogammaglobulinaemia in patients
enrolled in the phase III trial, and classified according to criteria
reported in Suppl. Table 2. Level of disability during activities
of daily living and health-related quality of life were assessed
using the Childhood Health Assessment Questionnaire
(CHAQ) and Euro QOL 5D 5 L (EQ5D5L; used in the phase
III trial) surveys, respectively, and results will be presented
separately. Treatment-emergent adverse events (TEAEs), ad-
verse drug reactions (ADRs), infusion-related reactions
(IRRs) and anti-drug antibodies (ADAs) were assessed
throughout the trials.
Statistical analysis
Baseline data were derived from the original trial in which
patients were enrolled. LO data were derived from the last
non-missing values collected per the protocol of the original
trial, or long-term follow-on trial. For patients randomised to
placebo in the phase III trial, the baseline for all evaluations
was the last non-missing value recorded immediately prior to
initiation of active treatment after study completion.
Integrated analysis data were evaluated in the overall popula-
tion and in age subgroups: adults (aged ≥18 years) and paedi-
atrics (aged <18 years). The absolute changes and percentage
changes from baseline to each time point were analysed for all
primary and secondary efficacy endpoints, using the paired t-
test and presented with their P-value and 95% CI.
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Results
Patients
Thirty-four patients participated in phase I/II and III trials and
received velmanase alfa treatment as part of rhLAMAN-07,
−09 or CU programme. Patient disposition is shown in Fig. 1.
Individual data from 33 patients were included in the integrat-
ed analysis. Fourteen patients were adult and 19 paediatric at
the time of first infusion. To date, six patients have
transitioned from being paediatric to adult patients during their
treatment period.
Baseline demographic and functional characteristics of
each patient are presented in Suppl. Table 1. All patients re-
ceived the intended clinical dose of 1 mg/kg/week (equal to
25 U used in the phase I/II study; Borgwardt et al 2014b) by
IV infusion for ≥12 months, and 19 (57.6%) received the
intended dose for ≥24 months. Mean (standard deviation,
SD) duration of exposure to treatment was 29.3 (15.2) months
(range: 11.7–53.4 months). The patient population initially
enrolled in the phase I/II studies (paediatric population aged
6–17 years), received velmanase alfa for up to 48 months
(Fig. 1). Treatment compliance was not assessed in this study,
but was reported as ≥90% in the phase I/II and III trials.
Efficacy endpoints
A statistically significant clearance of serum oligosaccharides
was observed in the overall population from baseline to
12 months (n = 31; mean change: −72.7% [95% CI: –81.4,
−64.1], P < 0.001) and remained statistically significant at LO
(n = 33; mean percentage change: −62.8% [95% CI: –74.7,
−50.8], P < 0.001). Similar results were seen across age groups
(Fig. 2a and Fig. 1a in the Supplementary material). A signifi-
cant improvement in 3MSCT was also observed at 12 months
(n = 31; mean change: +9.3% [95% CI: 2.14, 16.5], P = 0.013)
and this remained significant at LO (n = 33; mean change:
+13.8% [95% CI: 4.61, 22.92], P = 0.004) (Fig. 2b). A greater
improvement in 3MSCT was observed in paediatric patients,
compared with adults, at both 12 months (n = 18; +6.96
steps/min; +15.3%) and LO (n = 19; +10.7 steps/min; +23.1%)
(Fig. 2b and Fig. 1b in the Supplementary material). Paediatric
patients with the longest treatment exposure (48 months) expe-
rienced a mean absolute increase from baseline of 17.1 steps/
min (n = 9, +39.1%) at the end of follow-up.
A trend towards improved 6MWT was observed at
12 months and was statistically significant at LO (Table 1).
Paediatric patients experienced a greater increase in the
6MWT from baseline to the LO, compared with adult patients
(Table 1 and Fig. 2a in the Supplementary material. Four of
five paediatric and three of the five adult patients, requiring
walking help or aids (defined as cane, walker, crutches or
wheelchair in CHAQ Disability Index) at baseline became
independent at LO. A statistically significant mean absolute
change and percentage change in FVC (percentage predicted)
and FVC (L) was observed from baseline to 12 months and to
LO. The absolute change in FVC (percentage predicted and L)
was greater in paediatric vs adult patients at LO (Table 1 and
Fig. 2b in the Supplementary material. The BOT-2 total point
score for the entire group increased and the percentage change
was statistically significant at LO (P = 0.035; Table 1 and
Fig. 2c in the Supplementary material).
Results of additional secondary endpoints and PK analyses
are reported in the Suppl. Tables 2–8. Notably, biomarker
analysis did not show a significant change in cerebrospinal
fluid (CSF) biomarkers from baseline to LO (Suppl. Table 6).
Immunological status
A consistent and significant increase from baseline in mean
serum IgG concentrations was observed at 12 months (n = 22
[data only available for patients initially enrolled in the phase
III trial], mean percentage change: +47.0% [95% CI: 34.9,
59.1], P < 0.001) and at LO (n = 24; mean percentage change:
+44.1% [95% CI: 32.6, 55.6], P < 0.001), reversing clinically
relevant hypogammaglobulinaemia when present. Table 1
shows the improvements in patients’ serum immunoglobulin
status with treatment.
Safety
The incidence of treatment emergent adverse events (TEAEs)
is summarised in Table 2. More ADRs were reported in pae-
diatric patients, who had generally received more treatments.
Two patients experienced serious TEAEs that were considered
treatment-related: one patient experienced loss of conscious-
ness for 2–3 min 8 days after a velmanase alfa infusion; this
event resolved with no action taken regarding the study drug,
and the patient was subsequently diagnosed with epilepsy; the
second patient, who was receiving long-term high-dose ibu-
profen therapy (600 mg/day), experienced moderate intensity
acute renal failure that led to temporary discontinuation of
study treatment. The renal failure resolved after 92 days. No
TEAEs leading to permanent treatment discontinuation were
reported.
Nineteen IRRs were reported in three patients (9%).
Fourteen of the recorded IRRs occurred in one patient, who
withdrew from the phase I/II and discontinued therapy for
21 months, but subsequently enrolled in the phase III study
and is still receiving treatment. Eight patients (24.2%) devel-
oped ADAs at least once during treatment. At least one further
confirmatory ADA-positive result was present in six of these
patients, with ADAs levels around the cut off threshold. Two
patients had an ADA titre >80 U/ml (maximum values of
1012 U/ml and 440 U/ml respectively) and experienced IRRs.
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Discussion
In this integrated analysis of the long-term efficacy of
velmanase alfa treatment in patients with AM, statistically
significant improvements were observed in the co-primary
endpoints: serum oligosaccharide levels and 3MSCT.
Secondary endpoints evaluating endurance, pulmonary func-
tion and motor proficiency also showed improvements up to
48 months, which are particularly relevant in the context of a
progressively worsening disease. The long-term safety and
immunogenicity profile of velmanase alfa appears compatible
with chronic administration of the drug.
This study is a prospective integrated data analysis of
previous clinical trials with different designs (rhLAMAN-
02, −03, −04, −07 and − 09 are open-label, single-arm;
rhLAMAN-05 is randomised, double-blind, parallel-
group). The integrated study design was developed to ad-
dress the challenges of the rarity of AM and statistical
analyses of small patient populations. The study protocol
was written a priori and the statistical analysis plan de-
signed before database lock. The reason for choosing this
approach arises from the rarity of the condition and the
unusual possibility to be able to collect treatment data for
up to 4 years before marketing authorisation.
Phases I and II
rhLAMAN-02, -03, -04
N = 10
Phase III
rhLAMAN-05
N = 25
rhLAMAN-07
N = 7
rhLAMAN-09
N = 8
Compassionate use
programme
N = 20
rhLAMAN-10
data collection
N = 18
rhLAMAN-10
integrated analysis
N = 33
Patient in Phases I and II
Patient in Phases I, II and III (active)
Patient in Phase III (active)
Patient in Phase III (placebo)
N
 =
 3
4*
N
 =
 3
4
‡
§
56
56 58
42
58
67 42
42
42
56 58
58 did not enroll in
rhLAMAN-10
67 did not enroll
in rhLAMAN-10
Phase I
Trial
Paediatric
Patient population
Active
Treatment
Length of follow-up
in the rhLAMAN-10 study
48 months
48 months
48 months
12–36 months
Active
Active
Active vs Placebo
Paediatric
Paediatric
Adult/Paediatric
Phase IIa
Phase IIb
Phase III
Fig. 1 Patient disposition by
parental trial and by trial/CU
programme at the time of
enrolment in rhLAMAN-10
(enrolment in follow-up trial or
CU programme determined by
national regulations). * Patient 56
participated in rhLAMAN-02 and
rhLAMAN-03, discontinued
treatment due to an AE but later
enrolled in rhLAMAN-05. This
patient is only counted once
within the integrated analysis. ‡
Patient 58 participated in the
rhLAMAN-05 study in the active
arm. After completing the
rhLAMAN-05 study the patient
received velmanase alfa in the
compassionate use programme
but did not participate in the
rhLAMAN-10 study. Since the
subject received velmanase alfa
for 12 months in the rhLAMAN-
05 study, data from this patient are
included in the integrated
analysis. § Patient 67 participated
in the rhLAMAN-05 study in the
placebo arm and entered the
compassionate use programme
but did not participate in the
rhLAMAN-10 study. As this
patient did not have any data
collected during active treatment,
he was excluded from the
integrated analysis
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The presence of a control group limited to the 12-month
phase III trial (Borgwardt et al 2018) is, at least partially,
mitigated by the duration of the follow-up and the repeated
assessments.
Intra and inter-rater administrative reliability was
maximised by conducting all assessments at one site with
standardised administrative guidelines, and the same person-
nel collected the data on subsequent visits. The results of this
analysis clearly support the biochemical efficacy of velmanase
alfa treatment in patients with AM; marked decreases were
seen in serum oligosaccharide levels, and statistically sig-
nificant increases in serum immunoglobulins were ob-
served, with correction of hypogammaglobulinaemia in
many patients. Since the accumulation of mannose-rich
oligosaccharides is considered the causative mechanism
of cellular dysfunction and hypogammaglobulinaemia in
AM, alongside with oligosaccharide accumulation in lym-
phocytes, and is suspected to be the cause of the increase in
rate and severity of infections in AM patients (Malm et al
2000), these changes are assumed to produce a therapeutic
benefit (Malm et al 2014; Muenzer 2014). The decrease in
the proportion of patients who had impaired or seriously
impaired immunoglobulin levels supports the use of serum
immunoglobulin as an additional biomarker of velmanase
alfa activity. All treated patients benefited from an im-
provement of IgG in serum.
Performance in functional assessments can be influenced
by developmental stage, understanding of instructions and
willingness to cooperate, all of which can be problematic in
paediatric and/or cognitively disabled patients. These chal-
lenges, combined with the wide age range of study patients
(6–35 years), may partially account for inter- and intra-patient
variability. Six patients presented with concomitant condi-
tions, such as psychotic behaviour or knee pain, that have
compromised their endurance tests. As a severity score is
lacking in alpha-mannosidosis, patients’ disease burden was
evaluated at baseline based on the CHAQ disability index
(DI). The patient population included in the rhLAMAN10
study scored differently, ranging from severe to mild disabil-
ity. A post-hoc analysis revealed how, mean changes from
baseline to LO showed an improvement in all baseline
CHAQ-DI score groups in serum oligosaccharides, 3MWT,
6MWT and percentage of predicted FVC. As of today based
on the currently available data, no baseline characteristic can
be considered a predictive factor for VA treatment outcome. A
post-marketing registry study will help in broadening the un-
derstanding of the heterogeneity of the alpha-mannosidosis
population and the response to treatment.
The 3MSCTwas chosen as an advanced activities-of-daily-
living measure as it causes greater stress to the musculoskel-
etal and cardiorespiratory system, and requires a greater range
of motion and muscle strength, compared with level walking
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(Nightingale et al 2014). A clear improvement in 3MSCTwas
evident in the paediatric population, which is notable given
the progressive physical deterioration typically experienced
by patients with AM and provides evidence supporting the
effect of velmanase alfa treatment. In some patients, improved
3MSCT was also associated with a decreased reliance on
wheelchair use and other walking help or aids.
For many endpoints in this study, the observed improve-
ments were most marked in the paediatric population. To de-
termine whether the 3MSCT improvements in the paediatric
population were driven by growth alone, exploratory analyses
were conducted within the paediatric age groups of <12 years
and 12–17 years (representative of age groups characterised in
healthy children by a slower growth and performance devel-
opment in childhood vs the pubertal growth typical of adoles-
cence). Interestingly, mean improvements in 3MSCT were
similar between the two age groups at LO: +10.6 steps/min
(+28.5%) in patients <12 years and + 10.7 steps/min (+18.3%)
in patients aged 12–17 years, and thus not proportional to the
improvement rate expected by growth alone.
The positive results for the 6MWT are consistent with the
results from the 3MSCT and also suggest a mobility benefit
associated with velmanase alfa treatment. A greater increase
in FVC (% predicted) observed in the paediatric is also notable
given the poorer pulmonary function at baseline in paediatric
patients (mean FVC [%] at baseline 79.6% vs 92.5% in pae-
diatric and adult patients, respectively). The comparative im-
provements in motor and pulmonary function in those who
start treatment as paediatric patients, compared with those
who begin treatment as adults, suggest that patients may ben-
efit more from treatment started early in the disease course.
This observation is in line with previous studies of long-term
outcomes of patients receiving IV ERT for lysosomal storage
disorders, and supports that treatment of patients with such
disorders is recommended and should start early, preferably
pre-symptomatically, to obtain better long-term outcomes
(Muenzer 2014; Gabrielli et al 2010; McGill et al 2010;
Tylki-Szymanska et al 2012; Tajima et al 2013).
A reduction in serum oligosaccharides and an increase in
IgG levels were also achieved in adults. Clinically, these data
are highly relevant when considering the vulnerability of this
patient population to infections that can cause significant mor-
bidity. In addition, although the magnitude of the treatment
effect in domains such as endurance was smaller in adults com-
pared with paediatric patients, the observed level of improve-
ment or stabilisation in adults across all domains is still clini-
cally important because of the progressive nature of the under-
lying disease. Preservation of adequate pulmonary function and
maintenance of endurance and mobility in adult subjects may
lead to a better health-related quality of life than would be
associated with the gradual deterioration typical of AM.
Velmanase alfa was generally well tolerated throughout the
study. A conservative threshold of 1.4 U/ml (lower limit of
detection of the assay) was set with regard to detecting ADAs.
A limited number of patients developed ADAs, with no clear
effect on the co-primary efficacy outcomes (see also
Borgwardt et al 2017), despite for one of the two patients with
ADA > 80 U/ml who presented oligosaccharides above base-
line levels at LO. Three patients experienced IRRs, all of
which were mild or moderate in intensity and which resolved
either spontaneously or with medical management. Of note,
two of these patients had high levels of ADAs (>80 U/ml). A
clear correlation between ADA and IRR occurrence has never
been established in other therapies. Interestingly, the two
patients with highest titres of ADA in VA clinical develop-
ment programme developed IRR, suggesting the impor-
tance of keeping ADA monitoring in the future. The lim-
ited number of patients with high titre of ADA does not
allow driving conclusions for today and the future registry
study will help in providing new insights. The data were
Table 2 Summary of TEAEs by age and in the overall population
Paediatric
n = 19
Adult
n = 14
Overall
N = 33
Number of
events
Number of patients
(%)
Number of
events
Number of patients
(%)
Number of
events
Number of
patients (%)
Any TEAEs 423 17 (89.5) 123 12 (85.7) 546 29 (87.9)
ADRs 69 12 (63.2) 15 5 (35.7) 84 17 (51.5)
Serious TEAEs 9 7 (36.8) 5 5 (35.7) 14 12 (36.4)
Serious treatment-related
TEAEs
1 1 (5.3) 1 1 (7.1) 2 2 (6.1)
Severe TEAEs 3 2 (10.5) 1 1 (7.1) 4 3 (9.1)
TEAEs with a fatal outcome 0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
TEAEs leading to
discontinuation
0 0 (0.0) 0 0 (0.0) 0 0 (0.0)
ADR adverse drug reaction, TEAEs treatment-emergent adverse events
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collected longitudinally, and form the largest clinical
dataset evaluating ERT in AM to date. Our findings sug-
gest that the significant improvements in biochemical and
functional efficacy measures associated with velmanase
alfa may persist for up to 4 years in paediatric patients,
with adult patients experiencing significant improvements
in serum oligosaccharide levels and stabilisation of func-
tional performance up to 2 years after treatment initiation.
The long-term safety outcomes suggest that there are no
additional risks associated with extended treatment. The
lack of effect on CSF biomarkers is an area of unmet need
and a future research focus.
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